Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

A Cash Flow Statement

Operating, investing, and financing cash flow analysis

A Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
04/30/2026
01/31/2026
10/31/2025
07/31/2025
04/30/2025
01/31/2025
10/31/2024
07/31/2024
Cash from Operations (CFO)
1.452B277.000M268.000M545.000M362.000M221.000M431.000M481.000M452.000M
1.414B339.000M305.000M434.000M336.000M215.000M318.000M351.000M282.000M
Depreciation & Amortization
210.000M0.0067.000M71.000M72.000M73.000M72.000M69.000M63.000M
99.000M0.0041.000M26.000M32.000M30.000M40.000M26.000M28.000M
Change in Accounts Receivable
5.888B1.498B1.521B1.487B1.382B1.366B1.080B1.324B983.000M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-388.000M-211.000M-180.000M85.000M-82.000M-136.000M2.000M71.000M66.000M
Cash from Investing
-196.000M93.000M-93.000M-93.000M-103.000M-114.000M-97.000M-93.000M-92.000M
0.000.000.000.000.000.004.000M-859.000M-3.000M
Cash from Financing
Debt Repayment
-387.000M-65.000M-152.000M-85.000M-85.000M-165.000M-90.000M-335.000M-585.000M
-285.000M-72.000M-72.000M-70.000M-71.000M-70.000M-71.000M-68.000M-68.000M
1.256B370.000M175.000M452.000M259.000M107.000M334.000M388.000M360.000M
Net Change in Cash
320.000M49.000M-31.000M254.000M48.000M19.000M138.000M-450.000M108.000M

A Annual Cash Flow Statement (USD)

Annual Report
10/31/2025
10/31/2024
10/31/2023
10/31/2022
10/31/2021
10/31/2020
10/31/2019
10/31/2018
Cash from Operations (CFO)
1.559B1.751B1.772B1.312B1.485B921.000M1.021B1.087B
1.303B1.289B1.240B1.254B1.210B719.000M1.071B316.000M
Depreciation & Amortization
288.000M257.000M271.000M317.000M321.000M308.000M238.000M210.000M
128.000M129.000M111.000M125.000M110.000M83.000M72.000M70.000M
Change in Accounts Receivable
1.487B1.324B1.291B1.405B1.172B1.038B930.000M776.000M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-58.000M83.000M-116.000M-478.000M-102.000M-296.000M-388.000M471.000M
Cash from Investing
-407.000M-378.000M-298.000M-291.000M-189.000M-119.000M-156.000M-177.000M
4.000M-862.000M-1.000M-52.000M-546.000M1.000M-1.408B-516.000M
Cash from Financing
Debt Repayment
-425.000M-1.150B-575.000M-1.139B-788.000M-469.000M-723.000M-422.000M
-282.000M-274.000M-265.000M-250.000M-236.000M-222.000M-206.000M-191.000M
1.152B1.373B1.474B1.021B1.296B802.000M865.000M910.000M
Net Change in Cash
459.000M-261.000M537.000M-434.000M43.000M59.000M-866.000M-431.000M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell